Skip to main content
  1. Right Decisions
  2. Back
  3. Dermatology pathways
  4. Acne
Important: please update your RDS app to version 4.7.3

Welcome to the March 2025 update from the RDS team

1.     RDS issues - resolutions

1.1 Stability issues - Tactuum implemented a fix on 24th March which we believe has finally addressed the stability issues experienced over recent weeks.  The issue seems to have been related to the new “Tool export” function making repeated calls for content when new toolkit nodes were opened in Umbraco. No outages have been reported since then, and no performance issues in the logs, so fingers crossed this is now resolved.

1.2 Toolkit URL redirects failing– these were restored manually for the antimicrobial calculators on the 13th March when the issue occurred, and by 15th March for the remainder. The root cause was traced to adding a new hostname for an app migrated from another health board and made live that day. This led to the content management system automatically creating internal duplicate redirects, reaching the maximum number of permitted redirects and most redirects therefore ceasing to function.

This issue should not happen again because:

  • All old apps are now fully migrated to RDS. The large number of migrations has contributed to the high number of automated redirects.
  • If there is any need to change hostnames in future, Tactuum will immediately check for duplicates.

1.3 Gentamicin calculators – Incidents have been reported incidents of people accessing the wrong gentamicin calculator for their health board.  This occurs when clinicians are searching for the gentamicin calculator via an online search engine - e.g. Google - rather than via the health board directed policy route. When accessed via an external search engine, the calculator results are not listed by health board, and the start page for the calculator does not make it clearly visible which health board calculator has been selected.

The Scottish Antimicrobial Prescribing Group has asked health boards to provide targeted communication and education to ensure that clinicians know how to access their health board antimicrobial calculators via the RDS, local Intranet or other local policy route. In terms of RDS amendments, it is not currently possible to change the internet search output, so the following changes are now in progress:

  • The health board name will now be displayed within the calculator and it will be made clear which boards are using the ‘Hartford’ (7mg/kg) higher dose calculator
  • Warning text will be added to the calculator to advise that more than one calculator is in use in NHS Scotland and that clinicians should ensure they access the correct one for their health board. A link to the Right Decision Service list of health board antimicrobial prescribing toolkits will be included with the warning text. Users can then access the correct calculator for their Board via the appropriate toolkit.

We would encourage all editors and users to use the Help and Support standard operating procedure and the Editors’ Teams channel to highlight issues, even if you think they may be temporary or already noted. This helps the RDS team to get a full picture of concerns and issues across the service.

 

2.     New RDS presentation – RDS supporting the patient journey

A new presentation illustrating how RDS supports all partners in the patient journey – multiple disciplines across secondary, primary, community and social care settings – as well as patients and carers through self-management and shared decision-making tools – is now available. You will find it in the Promotion and presentation resources for editors section of the Learning and support toolkit.

3.     User guides

A new user guide is now available in the Guidance and tips section of Resources for providers within the Learning and Support area, explaining how to embed content from Google Calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream and Jotforms into RDS pages. A webinar for editors on using this new functionality is scheduled for 1 May 3-4 pm (booking information below.)

A new checklist to support editors in making all the checks required before making a new toolkit live is now available at the foot of the “Request a new toolkit” standard operating procedure. Completing this checklist is not a mandatory part of the governance process, but we would encourage you to use it to make sure all the critical issues are covered at point of launch – including organisational tags, use of Alias URLs and editorial information.

4.Training sessions for RDS editors

Introductory webinars for RDS editors will take place on:

  • Tuesday 29th April 4-5 pm
  • Thursday 1st May 4-5 pm

Special webinar for RDS editors – 1 May 3-4 pm

This webinar will cover:

  1. a) Use of the new left hand navigation option for RDS toolkits.
  2. b) Integration into RDS pages of content from external sources, including Google Calendar, Google Maps and simple Jotforms calculators.

Running usage statistics reports using Google analytics

  • Wednesday 23rd April 2pm-3pm
  • Thursday 22nd May 2pm-3pm

To book a place on any of these webinars, please contact Olivia.graham@nhs.scot providing your name, role, organisation, title and date of the webinar you wish to attend.

5.New RDS toolkits

The following toolkits were launched during March 2025:

SIGN guideline - Prevention and remission of type 2 diabetes

Valproate – easy read version for people with learning disabilities (Scottish Government Medicines Division)

Obstetrics and gynaecology induction toolkit (NHS Lothian) – password-protected, in pilot stage.

Oral care for care home and care at home services (Public Health Scotland)

Postural care in care homes (NHS Lothian)

Quit Your Way Pregnancy Service (NHS GGC)

 

6.New RDS developments

Release of the redesign of RDS search and browse, archiving and version control functionality, and editing capability for shared content, is now provisionally scheduled for early June.

The Scottish Government Realistic Medicine Policy team is leading development of a national approach to implementation of Patient-Reported Outcome Measures (PROMs) as a key objective within the Value Based Health and Care Action Plan. The Right Decision Service has been commissioned to deliver an initial version of a platform for issuing PROMs questionnaires to patients, making the PROMs reports available from patient record systems, and providing an analytics dashboard to compare outcomes across services.  This work is now underway and we will keep you updated on progress.

The RDS team has supported Scottish Government Effective Prescribing and Therapeutics Division, in partnership with Northern Ireland and Republic of Ireland, in a successful bid for EU funding to test develop, implement and assess new integrated care pathways for polypharmacy, including pharmacogenomics. As part of this project, the RDS will be working with NHS Tayside to test extending the current polypharmacy RDS decision support in the Vision primary care electronic health record system to include pharmacogenomics decision support.

7. Implementation projects

We have just completed a series of three workshops consulting on proposed improvements to the Being a partner in my care: Realistic Medicine together app, following piloting on 10 sites in late 2024. This app has been commissioned by Scottish Government Realistic Medicine to support patients and citizens to become active partners in shared decision-making and encouraging personalised care based on outcomes that matter to the person. We are keen to gather more feedback on this app. Please forward any feedback to ann.wales3@nhs.scot

 

 

Acne

Warning

Acne vulgaris: A common chronic inflammatory skin disorder affecting the pilosebaceous unit (i.e., the hair follicle and sebaceous gland) resulting in blockage of the follicle and immune mediated inflammation. Acne affects males and females of all races and ethnicities. All patients with acne should be offered clear information tailored to their needs and concerns. Consider referring to mental health services if a person with acne experiences significant psychological distress or mental health disorder.  

Not all treatment options may be listed in this guidance. Please refer to local formulary for a complete list.

Severity* 

*A universally accepted definition of acne severity does not exist. Overall severity is a clinical judgement based on multiple factors including previous treatment response, scarring and family history. Lesion counts are commonly used in research and the definitions provided are based on NICE 2021 guidelines purely as a guide. 

Mild - For mild to moderate acne, this includes people who have 1 or more of: any number of non-inflammatory lesions (comedones); up to 34 inflammatory lesions (with or without non-inflammatory lesions); up to 2 nodules. 

Self care- patients should be encouraged to use a non-alkaline synthetic cleansing product daily, avoid comedogenic products and avoid scratching or picking of lesions 

First line treatment options, taking into account severity and patient preference after a discussion of advantages and disadvantages: 

  • Fixed combination topical Adapalene with topical benzoyl peroxide (any acne severity) or; 
  • Fixed combination topical tretinoin with topical clindamycin (any acne severity) 
  • Fixed combination benzoyl peroxide with topical clindamycin (mild/moderate acne) 
  • Topical Azelaic acid (moderate to severe acne). 

 

Consider benzoyl peroxide monotherapy if above options contraindicated or patient wishes to avoid topical retinoids/antibiotics.  

 

Topical retinoids should not be prescribed in pregnant/breastfeeding women.  

 

*Please see key messages box below* 

Moderate - For mild to moderate acne, this includes people who have 1 or more of: any number of non-inflammatory lesions (comedones); up to 34 inflammatory lesions (with or without non-inflammatory lesions); up to 2 nodules.

Fixed combination topical benzoyl peroxide and topical adapalene OR topical azelaic acid twice daily in addition to an oral antibiotic for 12 weeks such as: 

  • Doxycycline 100mg OD   
  • Lymecycline (Tetralysal 300) 408mg OD 

 

If no improvement after 12 weeks then trial another antibiotic. If improvement noted after 12 weeks can continue for another 12 weeks but ideally not beyond a total of 6 months. Stop antibiotics as soon as possible.  

 

Tetracyclines can cause photosensitivity and are teratogenic. They should be avoided in children <12 years. Oral antibiotics may cause systemic side effects and antimicrobial resistance.  

 

Erythromycin or trimethoprim (unlicensed) can be considered if contraindications/ intolerance to tetracyclines. 

Trimethoprim can cause serious but rare side effects including agranulocytosis and severe cutaneous adverse reactions such as Stevens-Johnson syndrome. 

 

Macrolides are linked with high antimicrobial resistance and are not first line treatments. 

 

Hormonal Treatment Considerations: 

 

  • Progesterone only contraception may exacerbate acne. 
  • The type of progestin used in different combined contraceptive pills differ, as does their anti-androgenic action. For instance, levonorgestrel used in a number of commonly prescribed combined contraceptives has an increased androgenic potential compared with some other progestins. 
  • Ideally combined contraceptives should be used for females with acne who do also require a contraceptive. 
  • For women with polycystic ovary syndrome, treat as per first line management. If this is ineffective consider adding co-cyprindiol (Dianette®) or an alternative combined oral contraceptive.  
  • Those on co-cyprindiol should be reviewed at 6 months to assess need for continuation/other treatment options.  

Severe - For moderate to severe acne this includes people who have either or both of: 35 or more inflammatory lesions (with or without non-inflammatory lesions); 3 or more nodules

Treatment should be started in primary care as per moderate acne (combination oral antibiotics and topical treatment) whilst awaiting appointment with a consultant-led dermatology team for consideration of isotretinoin. 

Severity* 

*A universally accepted definition of acne severity does not exist. Overall severity is a clinical judgement based on multiple factors including previous treatment response, scarring and family history. Lesion counts are commonly used in research and the definitions provided are based on NICE 2021 guidelines purely as a guide. 

Mild - For mild to moderate acne, this includes people who have 1 or more of: any number of non-inflammatory lesions (comedones); up to 34 inflammatory lesions (with or without non-inflammatory lesions); up to 2 nodules. 

Can generally be managed in primary care 

Moderate - For mild to moderate acne, this includes people who have 1 or more of: any number of non-inflammatory lesions (comedones); up to 34 inflammatory lesions (with or without non-inflammatory lesions); up to 2 nodules.

Manage in primary care. Consider referral to consultant-led community or secondary care service if: 

- Mild to moderate acne has not responded to 2 completed courses of treatment (topical and oral) antibiotics.  

- Moderate to severe acne which has not responded to previous treatments containing an oral antibiotic. 

Severe - For moderate to severe acne this includes people who have either or both of: 35 or more inflammatory lesions (with or without non-inflammatory lesions); 3 or more nodules

Refer to consultant-led community or secondary care dermatology service in cases of: 

- diagnostic uncertainty  

- acne conglobata 

- nodulocystic acne 

Urgent same day referral should be made for cases of acne fulminans 

Consider referral in those with any severity who have scarring or persistent pigmentary change 

  • Topical Benzoyl Peroxide (BPO) containing preparations can reduce resistant C. Acnes developing when used alongside topical/oral antibiotics 
  • BPO and topical retinoids cause skin irritation, so should be introduced slowly (low-strength, low-frequency) and should be used alongside hydrating products. Short contact application initially (e.g. application for 1 hour then wash off) can help build skin tolerance. 
  • Do not use systemic monotherapy with a topical antibiotic, monotherapy with an oral antibiotic or topical and oral antibiotics in combination 
  • Spironolactone is an unlicensed treatment for acne in female patients. Practice differs amongst dermatologists but this can be a useful option in some women in whom advice regarding suitability from a dermatologist-led team may be useful. 
  • Consider referral to mental health services if acne is considerably affecting mental wellbeing including those with current/past history of anxiety/self- harm/suicidal ideation/body dysmorphic disorder. 
  • For all patients, regardless of severity, consideration of underlying causes such as drugs/other disease processes should be made with onward referral to specialists such as endocrinologists if deemed necessary.  

Inflammatory 

ICD11 code - ED80 

Editorial Information

Last reviewed: 24/05/2023

Next review date: 24/05/2025

Author(s): Adapted from the BAD Referral Guidelines.

Version: BAD 1

Co-Author(s): Publisher: Centre for Sustainable Delivery, Scottish Dermatological Society .

Approved By: Scottish Dermatological Society